Get started
Author

Amireh Heshmatkhah

Observed name: A Heshmatkhah
ORCID: 0000-0002-5471-0273
Observed ORCID: 0000-0002-5471-0273
OpenAlex ID: A5079420802
Associated-risk determinants for anthroponotic cutaneous leishmaniasis treated with meglumine antimoniate: A cohort study in Iran
2019 · Mohammad Reza Aflatoonian, Iraj Sharifi, et al. · PLoS neglected tropical diseases · 54
PDF
Efficacy of CO2 laser for treatment of anthroponotic cutaneous leishmaniasis, compared with combination of cryotherapy and intralesional meglumine antimoniate
2010 · S Shamsi Meymandi, S Zandi, et al. · Journal of the European Academy of Dermatology and Venereology · 52
Unresponsiveness to meglumine antimoniate in anthroponotic cutaneous leishmaniasis field isolates: analysis of resistance biomarkers by gene expression profiling
2018 · Razieh Tavakoli Oliaee, Iraj Sharifi, et al. · Tropical Medicine & International Health · 46
Quality of life in patients with cutaneous leishmaniasis.
2013 · Behrooze Vares, Mina Mohseni, et al. · PubMed · 46
A long-lasting emerging epidemic of anthroponotic cutaneous leishmaniasis in southeastern Iran: population movement and peri-urban settlements as a major risk factor
2021 · Taiebeh Karimi, Iraj Sharifi, et al. · Parasites & Vectors · 43
PDF
Major risk factors and histopathological profile of treatment failure, relapse and chronic patients with anthroponotic cutaneous leishmaniasis: A prospective case-control study on treatment outcome and their medical importance
2021 · Mehdi Bamorovat, Iraj Sharifi, et al. · PLoS neglected tropical diseases · 34
PDF
Adverse effects of intralesional meglumine antimoniate and its influence on clinical laboratory parameters in the treatment of cutaneous leishmaniasis
2012 · Iraj Esfandiarpour, Saeedeh Farajzadeh, et al. · International Journal of Dermatology · 33
Geographical distribution and molecular characterization for cutaneous leishmaniasis species by sequencing and phylogenetic analyses of kDNA and ITS1 loci markers in south-eastern Iran
2018 · Maryam Ramezany, Iraj Sharifi, et al. · Pathogens and Global Health · 28
Prophylactic effect of cutaneous leishmaniasis against COVID-19: a case-control field assessment
2021 · Mehdi Bamorovat, Iraj Sharifi, et al. · International Journal of Infectious Diseases · 21
PDF
A single-group trial of end-stage patients with anthroponotic cutaneous leishmaniasis: Levamisole in combination with Glucantime in field and laboratory models
2018 · Mehdi Bamorovat, Iraj Sharifi, et al. · Microbial Pathogenesis · 20
Poor adherence is a major barrier to the proper treatment of cutaneous leishmaniasis: A case-control field assessment in Iran
2022 · Mehdi Bamorovat, Iraj Sharifi, et al. · International Journal for Parasitology Drugs and Drug Resistance · 16
PDF
Topical terbinafine in the treatment of cutaneous leishmaniasis: triple blind randomized clinical trial
2015 · Saeedeh Farajzadeh, Amireh Heshmatkhah, et al. · Journal of Parasitic Diseases · 16
PDF
Comparison between intralesional injection of zinc sulfate 2 % solution and intralesional meglumine antimoniate in the treatment of acute old world dry type cutaneous leishmaniasis: a randomized double-blind clinical trial
2014 · Saeedeh Farajzadeh, Maryam Hakimi Parizi, et al. · Journal of Parasitic Diseases · 9
PDF
Cutaneous Leishmaniasis Hampers COVID-19: A Controlled Cross-Sectional Study in High-Burden Endemic Areas of Iran
2024 · Mehdi Bamorovat, Iraj Sharifi, et al. · Journal of Epidemiology and Global Health · 2
PDF
Works count: 16
Citation count: 430
H-index: 12
I10-index: 13
Year
Topic
Type